👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

Cathie Wood's ARK buys Tempus AI stock, sheds Palantir and Butterfly

Published 12/06/2024, 08:02 PM
TPX
-
PLTR
-

Cathie Wood's ARK ETFs have reported their daily trades for Friday, December 6th, 2024, showing a continued strategy of selective investment and divestment across the tech and healthcare sectors. Leading the trades with the highest dollar-value, ARK has made a significant purchase of Tempus AI Inc (NYSE:TEM), buying a combined total of 167,968 shares valued at approximately $8.9 million through its ARKK and ARKG ETFs.

In contrast, ARK has reduced its stake in Palantir Technologies Inc (NYSE:NASDAQ:PLTR), selling 95,570 shares for a total of nearly $6.9 million. This move comes as part of ARK's ongoing adjustments to its portfolio, possibly reflecting a shift in its long-term investment strategy or a response to market conditions.

The ETFs also continued to offload shares of Butterfly Network Inc (NYSE:BFLY), with a total of 294,071 shares sold, amounting to just over $973,000. This trade follows a pattern of selling seen in previous days, indicating ARK may be less bullish on the company's prospects or rebalancing for portfolio diversification.

Other trades of the day included a smaller sale of Senti Biosciences Inc (NASDAQ:SNTI), with 993 shares sold for a modest sum of $6,156. Although minor in value, this trade is part of a series of sales in the company's stock across recent days.

Looking at the week's activity, ARK has shown an accumulating interest in certain stocks, such as Tempus AI, while consistently reducing positions in others like Butterfly Network and Senti Biosciences. These moves provide insight into the ETFs' dynamic management approach, as they adapt to the ever-changing market landscape.

Investors following Cathie Wood's ARK ETFs will likely monitor these trades closely, seeking to understand the rationale behind the buying and selling patterns. As always, ARK's trades offer a window into the investment strategies of one of the most closely watched fund managers in the tech and healthcare investment spaces.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.